Bio Rad Laboratories (BIO) Stock Looks Fairly Valued After A 57% Slide

Bio-Rad Laboratories has produced a mixed experience for long term shareholders, with the stock down about 57.1% over five years, yet recent trading leaves it looking neither clearly cheap nor clearly expensive when compared with estimates of intrinsic value and market multiples.

• Over the past five years, Bio-Rad Laboratories’ share price has declined around 57.1%, which highlights how sensitive long term returns can be to the price paid versus the company’s fundamentals.
• The launch of Vericheck ddPCR kits for the QX700 System may support expectations around future demand in biopharma quality control, while execution risk around product adoption and competitive offerings can still weigh on how much investors are willing to pay for the stock.
• On Simply Wall St’s broader valuation checks, Bio-Rad Laboratories scores 1 out of 6, which leans expensive rather than a clear bargain even though the Discounted Cash Flow (DCF) estimate suggests the current price is close to intrinsic value and market multiples point to an overvalued reading.

The issue now is whether Bio-Rad Laboratories’ current price of about US$301.70 offers enough potential relative to these mixed valuation signals to justify taking on the risks embedded in the stock.

Find out why Bio-Rad Laboratories' 22.9% return over the last year is lagging behind its peers.

Is Bio-Rad Laboratories Fairly Priced on Cash Flow?

The Discounted Cash Flow (DCF) approach estimates what Bio-Rad Laboratories is worth today based on projected future cash generation. For the latest twelve months, the company produced around $343.4 million of free cash flow, and the model assumes these cash flows continue growing rather than shrinking over the next decade.

On those assumptions, the DCF model points to an intrinsic value of about $291 per share, which sits slightly below the current share price of around $301.70, implying the stock screens as around 3.6% overvalued. The launch of the Vericheck ddPCR kits is a concrete growth effort, but the current price already reflects cash flow expectations that are broadly in line with this outlook rather than offering a wide margin of safety.

Overall, the DCF workup suggests Bio-Rad Laboratories looks about fairly valued, with the share price sitting just above the model’s estimate of intrinsic worth.

Bio-Rad Laboratories is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Bio-Rad Laboratories.

Has Bio-Rad Laboratories Run Too Far on Earnings?

P/E is a useful yardstick for Bio-Rad Laboratories because earnings are a key focus for many investors in established life sciences businesses. Bio-Rad currently trades on a P/E of about 47.8x, which is above the Life Sciences industry average of roughly 38.0x and below the peer group average near 81.2x, so the stock sits between broader industry levels and higher rated peers.

On Simply Wall St’s fair P/E estimate of around 17.0x, which reflects the company’s profile relative to its growth prospects, margins, size and risk, Bio-Rad Laboratories is pricing in a much richer earnings multiple than that tailored benchmark. Even with the launch of Vericheck ddPCR kits in biopharma quality control supporting the business story, the current P/E implies investors are already paying a premium for each dollar of earnings.

On the P/E multiple alone, Bio-Rad Laboratories stock currently screens as overvalued relative to what the earnings profile would typically support.

See what the numbers say about this price — find out in our valuation breakdown.

The Bio-Rad Laboratories Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Bio-Rad Laboratories valuation puzzle leaves off by spelling out which combinations of future growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today's price on Simply Wall St's Community page. Each narrative links its number to a clear view on how Bio-Rad Laboratories' growth, profitability and risks might evolve, so you can come back to it as new information emerges.

Community views on Bio-Rad Laboratories sit on very different sides of the fence, with one camp leaning toward upside and the other highlighting valuation risk.

Bull case: 6% undervalued

"Automation, advanced data analytics, and digital transformation initiatives are set to yield stepwise improvements in operational efficiency and scale, enabling Bio-Rad to reduce SG&A expenses as a percentage of sales and directly boost operating and net margins…"

Read the full Bull Case to see why Bio-Rad Laboratories could be undervalued

Bear case: 10% overvalued

"Persistent global healthcare cost containment and increasing governmental price controls are expected to constrain reimbursement growth for diagnostics and laboratory products, placing a structural cap on Bio-Rad's long-term revenue expansion and challenging its ability to drive top-line growth as pricing pressure intensifies worldwide…"

Read the full Bear Case to see why Bio-Rad Laboratories could be overvalued

Do you think there's more to the story for Bio-Rad Laboratories? Head over to our Community to see what others are saying!

The Bottom Line

For Bio-Rad Laboratories, the Discounted Cash Flow (DCF) work suggests the current price sits close to intrinsic value, so the stock does not screen as a clear bargain or a clear mismatch on cash generation alone. Market multiples, particularly the richer P/E, tilt the picture toward overvalued, and broader valuation checks are not especially supportive. What matters most from here is whether Bio-Rad can deliver the earnings and margin profile that would justify that higher multiple, especially around adoption of products like the Vericheck ddPCR kits, or whether sentiment cools and the valuation premium fades.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com